Genetic tests

Full name Analytes Gene panels Disease Laboratory
Metastatic Breast or Pancreatic or Prostate Cancer BRCA1, BRCA2 Centrum Menselijke Erfelijkheid - KUL
Germline analysis of BRCA1/2 for iPARP treatment BRCA1, BRCA2 Germline analysis of BRCA1/2 for iPARP treatment Hereditary breast cancer Centre de Génétique Humaine - CHU Sart-Tilman
Breast Cancer Trial BRCA1, BRCA2 Centrum Menselijke Erfelijkheid - KUL
Somatic analysis of the BRCA genes (2 genes) BRCA1, BRCA2 Centrum Menselijke Erfelijkheid - KUL
Breast and Ovarian Cancer, HBOC, Familial (17 genes) BRCA1, BRCA2, TP53, PALB2, CHEK2, ATM, BRIP1, RAD51C, RAD51D, MLH1, MSH2, MSH6, BARD1, CDH1, EPCAM, PMS2, PTEN Hereditary breast and/or ovarian cancer syndrome Centre de Génétique Médicale UCL
Somatic analysis of the BRCA genes in the context of ovarian cancer treatment (2 genes) BRCA1, BRCA2 Centrum Medische Genetica - UZ Gent
Somatic analysis of the BRCA genes in the context of ovarian cancer treatment (2 genes) BRCA1, BRCA2 Centre de Génétique-Institut de Pathologie et de Génétique (IPG)
Breast and Ovarian Cancer, hereditary, HBOC, Familial (gene panel) BRCA1, BRCA2, PALB2, TP53, CHEK2, ATM, BRIP1, RAD51C, RAD51D, MLH1, MSH2, MSH6, BARD1 Breast/ ovarian cancer (12 genes) - UZA Hereditary breast cancer, Hereditary breast and/or ovarian cancer syndrome Centrum Medische Genetica - UZ Antwerpen
Breast and Ovarian cancer, HBOC, familial (gene panel - 17 genes) BRCA1, BRCA2, TP53, PALB2, CHEK2, BRIP1, RAD51C, RAD51D, MLH1, MSH2, MSH6, ATM Breast/Ovarian cancer (17 genes) - ULB Hereditary breast cancer Centre de Génétique Humaine - Erasme ULB
Hereditary Breast and Ovarian Cancer, HBOC (13 genes) BRCA1, BRCA2, TP53, PALB2, CHEK2, MLH1, MSH2, MSH6, BRIP1, BARD1, RAD51C, RAD51D, ATM Breast cancer, hereditary (13 genes) - ULG Hereditary breast cancer, Hereditary breast and/or ovarian cancer syndrome Centre de Génétique Humaine - CHU Sart-Tilman
Hereditary cancer (Breast, ovary, colon) (26 genes) BRCA1, BRCA2, BARD1, BRIP1, CDH1, MLH1, MSH2, MSH6, MEN1, PTEN, RAD50, RAD51D, STK11, TP53, CHEK2, MUTYH, PALB2, RAD51C, ATM, EPCAM, BLM, NBN, PMS2, XRCC2, ABRAXAS1, MRE11 Cancer (Breast, ovary, colon,…) (26 genes) - ULG Centre de Génétique Humaine - CHU Sart-Tilman
Somatic analysis of the BRCA genes in the context of ovarian cancer treatment (BRCA1; BRCA2 genes) BRCA1, BRCA2 Centre de Génétique Humaine - CHU Sart-Tilman
Dihydropyrimidine dehydrogenase deficiency/5-fluorouracil toxicity - Pharmacogenetics (4 variants: DPYD*2A, DPYD*13, c.2846A>T, HapB3) DPYD 5-fluorouracil toxicity Centrum Medische Genetica - UZ Antwerpen
5-fluorouracil (5-FU) toxicity - DPYD sequencing (all exons) - Pharmacogenetics DPYD 5-fluorouracil toxicity Centre de Génétique Médicale UCL
Dihydropyrimidine dehydrogenase deficiency (5-fluorouracil (5-FU) toxicity) - Pharmacogenetics DPYD 5-fluorouracil toxicity, Dihydropyrimidine dehydrogenase deficiency Centre de Génétique Humaine - CHU Sart-Tilman
5-fluorouracil toxicity - DPYD genotyping (4 hot spot mutations - DPYD*2A, DPYD*13, D949V, HapB3) - Pharmacogenetics DPYD 5-fluorouracil toxicity Centre de Génétique Médicale UCL
Dihydropyrimidine dehydrogenase deficiency; 5-fluorouracil toxicity - pharmacogenetics (4 variants: DPYD*2A, DPYD*13, c.2846A>T, HapB3) - Pharmacogenetics DPYD Dihydropyrimidine dehydrogenase deficiency Centrum Medische Genetica - UZ Gent
Dihydropyrimidine dehydrogenase deficiency/5-fluorouracil toxicity - Pharmacogenetics (4 variants: DPYD*2A, DPYD*13, c.2846A>T, HapB3) DPYD Dihydropyrimidine dehydrogenase deficiency Centrum Menselijke Erfelijkheid - KUL